A Phase 1 study to investigate the absorption, metabolism and excretion of 14C-Orteronel (TAK-700) following a single oral administration in healthy subjects

Completed

• Conditions: Prostate cancer; 10036958

• Registration Number: NL-OMON36117
• Lead Sponsor: Millenium Pharmaceuticals

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 6

Inclusion Criteria

Healthy male subject
18-55 years, incl
BMI 18-30 kg/m2, incl

Exclusion Criteria

Suffering from : hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of the study. In case of donating any blood or significant loss of blood within 60 days of the start of drug dosing.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>safety<br /><br>tolerability<br /><br>absorption, distribution, metabolizing and elimination</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>N/A</p><br>